2023 World Conference on Lung Cancer (Posters)-EP06.05. Computational Pathology-Based Assessment of cMET IHC Expression for Patient Selection in the Treatment of MET Overexpressing NSCLC

EP06.05. Computational Pathology-Based Assessment of cMET IHC Expression for Patient Selection in the Treatment of MET Overexpressing NSCLC - PDF(Abstract)

Back to course

Pdf Summary

This abstract discusses the use of computational pathology-based assessment of cMET IHC expression in the treatment of MET overexpressing non-small cell lung cancer (NSCLC). MET amplification is a common resistance mechanism to EGFR tyrosine kinase inhibitors in the treatment of EGFR mutated NSCLC. To identify patients who could benefit from additional MET blockade, histologic examination of immunohistochemically stained tissue or fluorescence in-situ hybridization are currently being used in clinical trials. <br /><br />The use of computational pathology-based tools, specifically Quantitative Continuous Scoring (QCS), allows for precise and accurate quantification of MET expression on tumor cells from IHC. This technology has the potential to improve scoring strategies and assay turnaround time. In a posthoc analysis of the SAVANNAH clinical trial, QCS was performed on centrally stained MET IHC slides from patients treated with savolitinib and osimertinib. A binary QCS biomarker positive or negative status was determined. <br /><br />The results showed that patients with QCS derived biomarker positive tumors had improved efficacy, as determined by a longer median progression-free survival (mPFS) compared to biomarker negative tumors. These findings were consistent with manual scores. <br /><br />In conclusion, this study reports the development and application of an image-analysis based computational pathology method for quantification of MET expression. The development and improvements of this technology will continue to be tested in future clinical trials.

Asset Subtitle

Simon Christ

Meta Tag

Speaker Simon Christ

Topic Pathology & Biomarkers

Keywords

computational pathology-based assessment

cMET IHC expression

MET overexpressing non-small cell lung cancer

EGFR tyrosine kinase inhibitors

histologic examination

immunohistochemically stained tissue

Quantitative Continuous Scoring (QCS)

MET expression

SAVANNAH clinical trial

progression-free survival (mPFS)